Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515788 · ClinicalTrials.gov registry record · Phase 1
DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00515788: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00515788 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00515788, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Objectives: \- To determine the safety, tolerability and maximum tolerated dose (MTD) of oral temozolomide using a 7 days on and 7 days off regimen combined with intrathecal liposomal cytarabine (DepoCyt) in patients with neoplastic meningitis from solid tumors and systemic lymphoma.
Interventions
- DRUG Temozolomide
- DRUG DepoCyt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515788
The ClinicalTrials.gov registry entry for NCT00515788 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00515788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00515788 about?
NCT00515788 is a clinical study titled "DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis". Objectives: \- To determine the safety, tolerability and maximum tolerated dose (MTD) of oral temozolomide using a 7 days on and 7 days off regimen combined with intrathecal liposomal cytarabine (DepoCyt) in patients with neoplastic meningitis from solid tumors and systemic lymphoma.
What is the current status of trial NCT00515788?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2006-02. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00515788?
The interventions under investigation include: Temozolomide (DRUG), DepoCyt (DRUG).
Who is sponsoring clinical trial NCT00515788?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.